HUMAW_OUT_1 [2025-04-17 11:42:16 -0400] 3392 Bytes | 874 tokens | Cum: 874 tkns (10.93% of 8k)
==========================================================================

We're scouting for winners today. Its 11:42:15 AM on Thu Apr 17, 2025 -0400 and I'm looking at Humacyte (HUMAW) up to 0.4100 from 0.3300

Help me investigate to see if its got potential or just another dud. So, I pulled together a bunch of data for you to look over real fast.

--- COMPANY PROFILE ---
Company: Humacyte (HUMAW)
IPO: 2021-08-27 (3 Years Ago)
Shares Outstanding: 119,840,000
Industry: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Exchange: XNAS
Description: Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Advanced Organ Systems, Advanced Tissue Constructs.

Here’s a list of headlines for Humacyte:

No news available.

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2025-03-26T10:18:34Z - US Stocks Likely To Open Lower After 3-Day Advance: Market Is Looking 'More Balanced' And Gone From 'Above-Trend To On-Trend,' Says Expert
B2 - 2025-01-21T15:44:00Z - DEADLINE ALERT for WOLF, HUMA, XRX, and ZETA: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
B3 - 2025-01-17T17:28:00Z - HUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud Lawsuit with the Schall Law Firm
B4 - 2025-01-17T15:47:00Z - HUMA DEADLINE TODAY: ROSEN, A TOP RANKED LAW FIRM, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important January 17 Deadline in Securities Class Action - HUMA
B5 - 2025-01-13T17:14:00Z - Humacyte, Inc. (HUMA) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
B6 - 2025-01-13T15:08:00Z - HUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud Lawsuit with the Schall Law Firm

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for Humacyte (HUMAW).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

HUMAW_OUT_3 [2025-04-17 11:42:16 -0400] 967 Bytes | 267 tokens | Cum: 1143 tkns (14.29% of 8k)
==========================================================================

Showing B2 (chunk 1 of 1): B2:
**DEADLINE ALERT for WOLF, HUMA, XRX, and ZETA: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/01/21/3012882/0/en/DEADLINE-ALERT-for-WOLF-HUMA-XRX-and-ZETA-The-Law-Offices-of-Frank-R-Cruz-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders.htmlThe Law Offices of Frank R. Cruz has filed class action lawsuits on behalf of shareholders of Wolfspeed, Humacyte, Xerox, and Zeta Global Holdings. The lawsuits allege that the companies made materially false and/or misleading statements about their business, operations, and prospects.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

HUMAW_OUT_5 [2025-04-17 11:42:17 -0400] 380 Bytes | 87 tokens | Cum: 1232 tkns (15.40% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

HUMAW_OUT_7 [2025-04-17 11:42:18 -0400] 336 Bytes | 98 tokens | Cum: 1332 tkns (16.65% of 8k)
==========================================================================

Showing A1 (chunk 1 of 1): A1:
Document A1 not found. Only 0 articles available.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

HUMAW_OUT_9 [2025-04-17 11:42:19 -0400] 238 Bytes | 59 tokens | Cum: 1393 tkns (17.41% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

HUMAW_OUT_11 [2025-04-17 11:42:19 -0400] 251 Bytes | 78 tokens | Cum: 1474 tkns (18.43% of 8k)
==========================================================================

You just read a chunk of S1.
You may now:
- Say "MOR" to continue this article
- Say "S2", "S3", etc. to request another
- Or say "NEX" to move to the next source

You are allowed up to 6 articles from this list. If you’re ready to move on, say NEX.

HUMAW_OUT_13 [2025-04-17 11:42:26 -0400] 4001 Bytes | 1099 tokens | Cum: 2576 tkns (32.20% of 8k)
==========================================================================

This is our set of metrics for Humacyte.
Please analyze the numbers.

No Finviz metrics available.

The next section covers any insider trading by Humacyte officers or majority shareholders (if available).

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -152867000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 0.35
Average Volume: 33715.96
30-Day High: 0.9873
30-Day Low: 0.2384

[Detailed Financials: Q3 2024]
- Total Assets: $114,764,000.0
- Total Liabilities: $178,485,000.0
- Total Equity: $-63,721,000.0
- Current Assets: $23,005,000.0
- Current Liabilities: $20,942,000.0

[Income Statement: Q3 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.33

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $-22,992,000.0

[Detailed Financials: Q2 2024]
- Total Assets: $138,281,000.0
- Total Liabilities: $166,568,000.0
- Total Equity: $-28,287,000.0
- Current Assets: $96,110,000.0
- Current Liabilities: $17,757,000.0

[Income Statement: Q2 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.48

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $-21,942,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of Humacyte (HUMAW).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about Humacyte.

2) MARKET_SCORE[]
This conversation was initiated because HUMAW is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for HUMAW.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, HUMAW could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect HUMAW to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of Humacyte.

11) ETHICAL_RATING[]
Rate Humacyte’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of Humacyte.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

HUMAW_IN_15 [2025-04-17 11:42:27 -0400] 126 Bytes | 29 tokens | Cum: 2783 tkns (34.79% of 8k)
==========================================================================

====================================
[2025-04-17 11:42:27] # Analysis Completed
Elapsed Time: 11.61 seconds